Core Viewpoint - The company has decided to repurchase and cancel a total of 220,300 restricted stocks due to the departure of certain incentive plan participants and performance evaluations not meeting the required standards [2][3][4]. Summary by Sections Repurchase and Cancellation Reasons - The repurchase is based on the departure of 10 participants from the 2022 incentive plan and 3 from the 2024 plan, leading to the cancellation of their stock options [2][3]. - A total of 241,300 restricted stocks were approved for repurchase, with 220,300 stocks actually being canceled due to one participant's stocks being frozen by the court [2][3]. Repurchase Details - The repurchase includes 168,700 stocks from the 2022 plan and 72,000 stocks from the 2024 plan, with repurchase prices set at 15.65 yuan and 18.09 yuan per stock respectively [3][4]. - The company has established a dedicated securities account for the repurchase process and expects the cancellation to be completed by October 9, 2025 [5]. Impact on Share Structure - After the cancellation, the remaining restricted stocks will total 6,382,480, and the repurchase will not affect the control of the company or its compliance with listing conditions [5][6]. Compliance and Legal Opinions - The board has confirmed that the decision-making process and disclosures comply with relevant regulations and that there are no violations of the rights of the incentive participants or creditors [7][8]. - Legal counsel has affirmed that the repurchase has received necessary approvals and adheres to applicable laws and regulations [8].
甘李药业股份有限公司 关于2022年、2024年限制性股票激励计划部分限制性股票回购注销实施公告